Tassos Konstantinou

The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK.

Sloane Robinson LLP is the alternative investment management subsidiary of Sloane Robinson Investment Services Ltd. in Great Britain. The firm was founded by Hugh Sloane and George Robinson in 1993 as Sloane Robinson Investment Management Ltd. They changed their name to Sloane Robinson Investment Partners LLP in 2004. Headquartered in London, Sloane Robinson manages assets with an absolute return focus on behalf of professional investors throughout the world.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

John Swire & Sons (H.K.) Ltd. is an investment holding company. The company was founded on October 30, 1947 and is headquartered in Hong Kong.

Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

hte AG the high throughput experimentation Co. provides technology, experimentation, and research and development solutions. The company’s solution areas cover hardware and software systems, project development, and research implementation activities. The firm specializes in catalyst testing, process optimization, laboratory automation, workflow management, training, and technical support. The company was founded by Wolfram Stichert in 1999 and is headquartered in Heidelberg, Germany.

UCL Business Plc operates as a technology transfer company. The company was founded in 2002 and is headquartered in London, the United Kingdom.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Oxford Photovoltaics Ltd. develops and commercialize perovskite-based technology. Its technology can be coated on architectural glass to allow large buildings to generate a significant proportion of their electricity demand, effectively turning them into vertical solar farms. The firm investors include MTI partners, Longwall Venture Partners LLP, Parkwalk, University of Oxford (OSEM). The company was founded by Kevin Arthur and Henry Snaith in December 2010 and is headquartered in Kidlington, the United Kingdom.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

The Maggie Keswick Jencks Cancer Caring Centres Trust provides free practical, emotional, and social support services to people with cancer. The non-profit company is based in Edinburgh, UK. The British company was founded in 1996 by Maggie Keswick Jencks and Charles Jencks. Dame Laura Lee has been the CEO of the company since 1998.

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

Oxford Investment Consultants LLP (Oxford Investment Consultants) is a venture capital firm founded in 2015 by George Edward Silvanus Robinson and Ross Hyett. The firm is headquartered in Oxford, London.

Bodle Technologies Ltd. provides advanced optoelectronic solutions for revolutionary displays and smart windows. The company was founded by David Fyfe, Harish Bhaskaran, and Peiman Hosseini in 2015 and is headquartered in Begbroke, the United Kingdom.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom.

Cripps Barn Group Ltd. operates a wedding venue.

Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom.

Macomics Ltd. engages in research and experimental development on biotechnology. The company was founded by Jeffrey William Pollard and Luca Cassetta on November 6, 2018 and is headquartered in Edinburgh, the United Kingdom.

Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022.

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.

Epidarex Exeed Ltd. is a British biotechnology company that specializes in research and experimental development. The company is based in Edinburgh, UK. The company was founded in 2019 by Elizabeth Ann Roper and Henning Steinhagen, with Henning Steinhagen serving as the CEO since its inception.